BRPI0918791A2 - anticorpo monoclonal anti- igm humana, fragmento funcional, teste de imunoaglutinação, reagente de teste de imunoaglutinação e kit de teste de imunoaglutinação, hibridoma, método de produzir um anticorpo monoclonal anti- igm humana agente, imunoteste, e reagente de imunoteste e kit de imunoteste - Google Patents

anticorpo monoclonal anti- igm humana, fragmento funcional, teste de imunoaglutinação, reagente de teste de imunoaglutinação e kit de teste de imunoaglutinação, hibridoma, método de produzir um anticorpo monoclonal anti- igm humana agente, imunoteste, e reagente de imunoteste e kit de imunoteste

Info

Publication number
BRPI0918791A2
BRPI0918791A2 BRPI0918791A BRPI0918791A BRPI0918791A2 BR PI0918791 A2 BRPI0918791 A2 BR PI0918791A2 BR PI0918791 A BRPI0918791 A BR PI0918791A BR PI0918791 A BRPI0918791 A BR PI0918791A BR PI0918791 A2 BRPI0918791 A2 BR PI0918791A2
Authority
BR
Brazil
Prior art keywords
immunotest
monoclonal antibody
reagent
kit
human igm
Prior art date
Application number
BRPI0918791A
Other languages
English (en)
Inventor
Hiroshi Takahashi
Tomo Shimizu
Yasushi Nakamura
Yuki Takahashi
Original Assignee
Sekisui Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Medical Co Ltd filed Critical Sekisui Medical Co Ltd
Publication of BRPI0918791A2 publication Critical patent/BRPI0918791A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545Synthetic resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302Apparatus specially adapted for immunological test procedures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541Double or second antibody, i.e. precipitating antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/686Anti-idiotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0918791A 2008-09-05 2009-09-03 anticorpo monoclonal anti- igm humana, fragmento funcional, teste de imunoaglutinação, reagente de teste de imunoaglutinação e kit de teste de imunoaglutinação, hibridoma, método de produzir um anticorpo monoclonal anti- igm humana agente, imunoteste, e reagente de imunoteste e kit de imunoteste BRPI0918791A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008228370 2008-09-05
JP2008272642 2008-10-23
JP2008286521 2008-11-07
PCT/JP2009/004350 WO2010026758A1 (ja) 2008-09-05 2009-09-03 モノクローナル抗体及びこれを用いた免疫学的測定方法

Publications (1)

Publication Number Publication Date
BRPI0918791A2 true BRPI0918791A2 (pt) 2016-10-25

Family

ID=41796939

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918791A BRPI0918791A2 (pt) 2008-09-05 2009-09-03 anticorpo monoclonal anti- igm humana, fragmento funcional, teste de imunoaglutinação, reagente de teste de imunoaglutinação e kit de teste de imunoaglutinação, hibridoma, método de produzir um anticorpo monoclonal anti- igm humana agente, imunoteste, e reagente de imunoteste e kit de imunoteste

Country Status (11)

Country Link
US (2) US20110165701A1 (pt)
EP (2) EP2322562B1 (pt)
JP (2) JP4625879B2 (pt)
KR (1) KR101729056B1 (pt)
CN (1) CN102159591A (pt)
AU (2) AU2009287916A1 (pt)
BR (1) BRPI0918791A2 (pt)
CA (2) CA2964771C (pt)
MX (1) MX2011002337A (pt)
MY (2) MY171554A (pt)
WO (1) WO2010026758A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322562B1 (en) * 2008-09-05 2016-03-30 Sekisui Medical Co., Ltd. Monoclonal antibody, and immunoassay using same
CA2739310C (en) * 2009-07-21 2014-07-08 Sekisui Medical Co., Ltd. Insulin assay
WO2014051144A1 (ja) 2012-09-28 2014-04-03 積水メディカル株式会社 免疫学的検出方法および免疫学的検出試薬
US9313814B2 (en) * 2013-12-20 2016-04-12 Intel Corporation Establishing wireless communication via proximity detection
JP6005705B2 (ja) * 2014-09-25 2016-10-12 ヤマサ醤油株式会社 非特異的反応阻害剤、それを用いた免疫学的測定法
CN104407159B (zh) * 2014-12-15 2016-03-02 山东博科生物产业有限公司 一种免疫球蛋白IgM免疫比浊法检测试剂盒
CN105334318A (zh) * 2015-11-28 2016-02-17 宁波美康生物科技股份有限公司 一种便捷式c反应蛋白检测试剂盒
WO2018203572A1 (ja) * 2017-05-02 2018-11-08 田中貴金属工業株式会社 非特異反応抑制剤
JP6962834B2 (ja) * 2018-02-21 2021-11-05 田中貴金属工業株式会社 モノクローナル抗体および非特異反応抑制剤
JP6943789B2 (ja) 2018-02-21 2021-10-06 田中貴金属工業株式会社 モノクローナル抗体および非特異反応抑制剤
CN108531460B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
CN108517316B (zh) * 2018-03-30 2020-08-11 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
CN108330104B (zh) * 2018-03-30 2019-10-18 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
CN109444426A (zh) * 2018-12-12 2019-03-08 郑州安图生物工程股份有限公司 消除捕获法IgM抗体检测系统中HAMA干扰的方法
WO2023088443A1 (zh) * 2021-11-20 2023-05-25 东莞市朋志生物科技有限公司 一种抗人IgM抗体及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164558A (en) * 1976-11-22 1979-08-14 Massachusetts Institute Of Technology Method for optimizing reagents for agglutination reactions
JPS6042400A (ja) 1983-08-19 1985-03-06 Yamasa Shoyu Co Ltd ヒトIgMに対する単一クロ−ン抗体
JPH0736016B2 (ja) * 1984-05-11 1995-04-19 和光純薬工業株式会社 免疫グロブリンの定量方法
DE3662730D1 (en) * 1985-01-24 1989-05-11 Inst Int Pathologie Cellulaire Immunoassay method for antibodies of different classes in a liquid sample
JPS6358260A (ja) 1986-08-29 1988-03-14 Chemo Sero Therapeut Res Inst IgM型抗体の測定法
US5079173A (en) * 1987-08-19 1992-01-07 Shionogi & Co., Ltd. Methods, hybridomas, monoclonal antibodies and sensitized cells for measuring hbs antigen
JPH01144993A (ja) * 1987-08-19 1989-06-07 Shionogi & Co Ltd HBs抗原測定のための方法、ハイブリドーマ、モノクローナル抗体および感作血球
JPH01305697A (ja) 1988-06-02 1989-12-08 Yamatake Honeywell Co Ltd 通信システム
IE911172A1 (en) 1990-04-27 1991-11-06 Res Dev Foundation MONOCLONAL ANTI-IgM ANTIBODIES, THEIR PRODUCTION AND USE,¹AND HYBRIDOMAS FOR PRODUCING THE SAME
WO1993016729A1 (en) * 1992-02-28 1993-09-02 Biotransplant, Inc. Antibodies for and treatment to prevent or reduce the severity of xenograft rejection
JPH0712818A (ja) 1993-06-25 1995-01-17 Hitachi Chem Co Ltd 免疫学的検出方法
JPH08327629A (ja) * 1995-06-01 1996-12-13 Fujirebio Inc 検体前処理方法
JP4065600B2 (ja) 1998-04-01 2008-03-26 デンカ生研株式会社 免疫学的測定法および免疫学的測定用キット
JP2002048798A (ja) * 2000-05-24 2002-02-15 Mitsubishi Chemicals Corp 金属または金属化合物を含有する標識粒子を用いる測定方法
JP2003294753A (ja) * 2002-04-01 2003-10-15 Kyokuto Seiyaku Kogyo Kk 凝集反応増感剤、免疫測定用試薬及び免疫測定法
EP1460426A1 (en) * 2003-03-20 2004-09-22 Sysmex Corporation Method for detecting antibody against BDV (Borna disease virus) for detecting a BDV infection
JP2004309477A (ja) * 2003-03-26 2004-11-04 Sysmex Corp 抗体測定方法
WO2007013157A1 (ja) * 2005-07-28 2007-02-01 Kabushiki Kaisha Yakult Honsha 抗体感作ラテックス
EP2322562B1 (en) * 2008-09-05 2016-03-30 Sekisui Medical Co., Ltd. Monoclonal antibody, and immunoassay using same

Also Published As

Publication number Publication date
KR101729056B1 (ko) 2017-04-24
KR20110059753A (ko) 2011-06-03
CA2734704C (en) 2017-06-20
WO2010026758A1 (ja) 2010-03-11
CA2964771A1 (en) 2010-03-11
AU2016203292B2 (en) 2018-06-07
JP5570391B2 (ja) 2014-08-13
CA2964771C (en) 2019-01-15
JP4625879B2 (ja) 2011-02-02
EP2322562A1 (en) 2011-05-18
EP2322562A4 (en) 2012-10-10
EP2322562B1 (en) 2016-03-30
CA2734704A1 (en) 2010-03-11
AU2016203292A1 (en) 2016-06-09
AU2009287916A1 (en) 2010-03-11
JP2011027751A (ja) 2011-02-10
MY171554A (en) 2019-10-18
EP3056517A1 (en) 2016-08-17
US20160341721A1 (en) 2016-11-24
CN102159591A (zh) 2011-08-17
EP3056517B1 (en) 2017-11-29
MX2011002337A (es) 2011-04-05
US20110165701A1 (en) 2011-07-07
MY189968A (en) 2022-03-22
JPWO2010026758A1 (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
BRPI0918791A2 (pt) anticorpo monoclonal anti- igm humana, fragmento funcional, teste de imunoaglutinação, reagente de teste de imunoaglutinação e kit de teste de imunoaglutinação, hibridoma, método de produzir um anticorpo monoclonal anti- igm humana agente, imunoteste, e reagente de imunoteste e kit de imunoteste
BRPI0908508A2 (pt) anticorpo monoclonal nkg2a anti-humano humanizado
BRPI0822447A2 (pt) Anticorpo monoclonal e método do mesmo
CR20110577A (es) Proteínas de unión a il-1
DOP2011000404A (es) Polipeptidos y metodo de tratamiento
CL2008000278A1 (es) Anticuerpo monoclonal anti-hepcidina humana; acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; kit de inmunoensayo que lo comprende; metodo para diagnosticar y tratar un trastorno relacionado
MY144980A (en) Method for rapid detection of lymphatic filariasis
DK2569013T3 (da) Humaniserede og kimære monoklonale antistoffer til cd47
BRPI0916915A2 (pt) anticorpos anti-il-17a/f de reatividade cruzada e biespecíficos
IL202232A0 (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
BR112012019475A8 (pt) uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
ECSP12011761A (es) Moléculas de anticuerpo anti-gcc y composiciones y métodos relacionados.
IL211742A (en) Isolated monoclonal antibodies specifically associated with frizzled receptor and various aspects thereof
BR112013027021A2 (pt) anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI0906903B8 (pt) anticorpo monoclonal e método de detecção da expressão de cd70
WO2010049672A3 (en) Methods and products for measuring free immunoglobulin light chain molecules
ATE465179T1 (de) Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
BRPI1005176A2 (pt) ensaio de insulina, reagente de ensaio de insulina, anticorpo monoclonal, e, método de triar anticorpos monoclonais.
BR112013013573A2 (pt) método para produzir anticorpos específicos para um antígeno de interesse, célula b isolada ou recombinante, população de anticorpo, e, anticorpo
BR112012025082A2 (pt) novos anticorpos monoclonais e método de análise imunológica de dímero-d
WO2008101177A3 (en) Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements